Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 77Gastrointestinal 11CNS 11Head & Neck 8Gynecologic 6Genitourinary 5Tumor-Agnostic 2Thoracic 2Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Lapatinib × Genitourinary × Clear all
NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

University of Southern California

Phase 2 Terminated
15 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00953576 2018-09-04

KHLAD

Dana-Farber Cancer Institute

Phase 1/2 Terminated
11 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT00246753 2017-06-28

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
29 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00103194 2014-09-30

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
49 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡